UBS Group’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

UBS Group’s Portfolio NRSNW Stock Details NRSNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64	Hold	1,163	–	–	﹤0.01%	10178
2025 Q4	$291	Sell	1,163 -117	-9%	-$42	﹤0.01%	10055
2025 Q3	$397	Sell	1,280 -190	-13%	-$114	﹤0.01%	9695
2025 Q2	$932	Sell	1,470 -1,371	-48%	-$535	﹤0.01%	9704
2025 Q1	$582	Buy	2,841 +2,747	+2,922%	+$718	﹤0.01%	9724
2024 Q4	$41	Sell	94 -106	-53%	-$28	﹤0.01%	9723
2024 Q3	$28	Sell	200 -405	-67%	-$69	﹤0.01%	9284
2024 Q2	$125	Buy	+605	New	+$139	﹤0.01%	9131
2023 Q4	–	Sell	-3,802	Closed	-$422	–	9715
2023 Q3	$422	Buy	+3,802	New	+$692	﹤0.01%	8507
2023 Q1	–	Sell	-798	Closed	-$128	–	10113
2022 Q4	$128	Sell	798 -1,160	-59%	-$293	﹤0.01%	10370
2022 Q3	$0	Buy	+1,958	New	+$506	﹤0.01%	10727
2022 Q1	–	Sell	-4,491	Closed	-$4K	–	10687
2021 Q4	$4K	Buy	+4,491	New	+$4K	﹤0.01%	9532

Other funds holding NRSNW

EAM

Empery Asset Management New York $83M AUM

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

UBS Group's NRSNW Position: Q1 2026 in Review

UBS Group held its NeuroSense Therapeutics Warrant (NRSNW) position steady in Q1 2026 at 1,163 shares worth $64. The position accounts for ﹤0.01% of the portfolio, ranked #10178.

UBS Group first reported a position in NRSNW in Q4 2021 and has held it in 12 quarters since. The position peaked at $4K in Q4 2021. 3 funds tracked by Wall St. Rank hold NRSNW as of Q1 2026.

UBS Group held 1,163 shares of NeuroSense Therapeutics Warrant worth $64 as of Q1 2026.
UBS Group left its NeuroSense Therapeutics Warrant share count unchanged in Q1 2026.
NeuroSense Therapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10178 holding.
UBS Group first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and has held it in 12 quarters since.
UBS Group's NeuroSense Therapeutics Warrant position peaked at $4K in Q4 2021.
3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.